Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 29, 2015 3:45 PM ET

Capital Markets

Company Overview of BB Biotech AG

Company Overview

BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domiciled in Switzerland.

Seestrasse 16

Kusnacht,  CH-8700

Switzerland

Founded in 1993

Key Executives for BB Biotech AG

Head of Biotech, Portfolio Manager, and Member of Executive Board
Age: 44
Chief Financial Officer
Member of Management Team
Member of Management Team
Analyst and Portfolio Manager Biotech
Compensation as of Fiscal Year 2014.

BB Biotech AG Key Developments

BB Biotech Reports Earnings Results for the First Quarter of 2015

BB Biotech reported earnings results for the first quarter of 2015. For the quarter, the company announced that its net profit soared to CHF 379.4 million, boosted by pipeline progress and M&A activity involving its portfolio companies. Net profit in the prior-year period stood at CHF 65.7 million. Net asset value grew by 10.6% in CHF, 27.5% in EUR and 13% in USD over the reporting period. The major growth drivers in the period were mid-cap firms Pharmacyclics, Incyte and Neurocrine, while larger cap holdings did not keep up with benchmark performance, with the exception of Novo Nordisk.

BB Biotech AG Approves Cash Distribution for the Year 2014, Payable on March 24, 2015

Shareholders at BB Biotech AG's AGM vote to approved cash distribution of CHF 11.60 per share for the year 2014. Since this distribution will be made from paid-in capital reserves, it is exempt from Swiss withholding tax. Payment will be made on March 24, 2015 and the date of record is March 23, 2015.

BB Biotech AG Announces Cash Distribution for 2014

BB Biotech AG announced that in line with the distribution policy established in 2013, the Board of Directors will propose a tax-efficient cash distribution of CHF 11.60 per share at the Annual General Meeting. This represents a significant increase of 65% compared to the previous year and corresponds to a yield of 5% based on the volume weighted average share price in December 2014.

Similar Private Companies By Industry

Company Name Region
Fairfield Partners LLC Europe
NZB Neue Zuercher Bank AG Europe
TRIUM Corporate Finance AG Europe
SISM Research & Investment Services Europe
IC Day Trading Consulting Corp. Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BB Biotech AG, please visit www.bellevue.ch/cms/lang/en/home/bellevue_asset_management/investment_products/CH0038389992/CH003838. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.